Reiser M, et al. - In this prospective, multicenter, observational study, researchers assessed the real-world efficacy and tolerability of rituximab-containing chemoimmunotherapies in chronic lymphocytic leukemia (CLL) patients. They also analyzed current treatment patterns in clinical practice and compared an unselected real-life population with older, comorbid patients. Rituximab-bendamustine was most commonly used to treat both first-line and relapsed patients. For cohort 1 (unselected) and cohort 2 (comorbid), the observed two-year progression-free survival rate was 84.1% and 69.8%, respectively (with best overall response rate 81.8% for cohort 1 and 76.6% for cohort 2). Overall, feasibility, as well as the safety of chemoimmunotherapy with rituximab was seen in a wide variety of clinical settings in CLL, including the treatment of older patients with comorbidities.